Cogent Biosciences, Inc. (COGT)
COGT Stock Price Chart
Explore Cogent Biosciences, Inc. interactive price chart. Choose custom timeframes to analyze COGT price movements and trends.
COGT Company Profile
Discover essential business fundamentals and corporate details for Cogent Biosciences, Inc. (COGT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
29 Mar 2018
Employees
205.00
Website
https://www.cogentbio.comCEO
Andrew R. Robbins
Description
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
COGT Financial Timeline
Browse a chronological timeline of Cogent Biosciences, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Aug 2026
EPS estimate is -$0.55, while revenue estimate is $1.00k.
Earnings released on 5 May 2026
EPS came in at -$0.53 matching the estimated -$0.53.
Earnings released on 17 Feb 2026
EPS came in at -$0.55 falling short of the estimated -$0.51 by -7.84%.
Earnings released on 7 Nov 2025
EPS came in at -$0.50 surpassing the estimated -$0.54 by +7.41%.
Earnings released on 5 Aug 2025
EPS came in at -$0.53 surpassing the estimated -$0.55 by +3.64%.
Earnings released on 6 May 2025
EPS came in at -$0.52 surpassing the estimated -$0.56 by +7.14%.
Earnings released on 25 Feb 2025
EPS came in at -$0.09 surpassing the estimated -$0.59 by +84.75%.
Earnings released on 12 Nov 2024
EPS came in at -$0.64 falling short of the estimated -$0.55 by -16.36%.
Earnings released on 6 Aug 2024
EPS came in at -$0.59 falling short of the estimated -$0.55 by -7.27%.
Earnings released on 7 May 2024
EPS came in at -$0.62 falling short of the estimated -$0.50 by -24.00%.
Earnings released on 26 Feb 2024
EPS came in at -$0.63 falling short of the estimated -$0.54 by -16.67%, while revenue for the quarter reached $5.59m .
Earnings released on 2 Nov 2023
EPS came in at -$0.64 falling short of the estimated -$0.50 by -28.00%.
Earnings released on 8 Aug 2023
EPS came in at -$0.59 falling short of the estimated -$0.53 by -11.32%.
Earnings released on 9 May 2023
EPS came in at -$0.54 surpassing the estimated -$0.58 by +6.90%.
Earnings released on 14 Mar 2023
EPS came in at -$0.56 falling short of the estimated -$0.50 by -12.00%.
Earnings released on 14 Nov 2022
EPS came in at -$0.50 surpassing the estimated -$0.51 by +1.96%.
Earnings released on 9 Aug 2022
EPS came in at -$0.71 falling short of the estimated -$0.64 by -10.94%.
Earnings released on 10 May 2022
EPS came in at -$0.68 falling short of the estimated -$0.53 by -28.30%.
Earnings released on 15 Mar 2022
EPS came in at -$0.61 falling short of the estimated -$0.55 by -10.91%.
Earnings released on 10 Nov 2021
EPS came in at -$0.48 falling short of the estimated -$0.43 by -11.63%.
Earnings released on 16 Aug 2021
EPS came in at -$0.43 falling short of the estimated -$0.39 by -10.26%.
COGT Stock Performance
Access detailed COGT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
